Skip to main content

Arrivent Biopharma

ArriVent BioPharma Inc is an American clinical-stage biopharmaceutical enterprise specializing in the discovery, development, and commercialization of innovative medicines designed to address unmet medical needs in oncology, prominently featuring targeted therapies for advanced solid tumors and non-small cell lung cancer (NSCLC) harboring specific genetic mutations (such as HER2 and EGFR mutations). The company conducts advanced clinical trials evaluating precision oncology drug candidates, including its lead product candidate furmonertinib. Its core business operations encompass biopharmaceutical research, clinical trial execution, precision oncology drug development, and regulatory navigation. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through venture capital financing, public equity offerings, and strategic licensing partnerships. ArriVent BioPharma holds an established market position in precision oncology and targeted lung cancer drug development. The company is headquartered in Newtown, Pennsylvania, United States, and its common stock trades on the Nasdaq Global Select Market under the ticker AVBP.

2 of the funds FundTelligence covers report a position in Arrivent Biopharma.

Legal name
Arrivent Biopharma Inc
Sector
Health Care
Country
United States
Funds holding it
2
Exposure themes
Precision Medicine & Genomics, Precision Oncology, Precision Therapeutics

Funds holding Arrivent Biopharma

Loading...